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doi:10.101Hepatitis B Virus Reactivation following Allogeneic
Hematopoietic Stem Cell Transplantation
Sarah P. Hammond,1,2,3 Anne Marie Borchelt,1 Chinweike Ukomadu,2,3,4 Vincent T. Ho,2,3,5
Lindsey R. Baden,1,2,3 Francisco M. Marty1,2,3Reactivation of resolved hepatitis B virus (HBV) infection has been reported in allogeneic hematopoetic stem
cell transplantation (HSCT) recipients, but its epidemiology is not well characterized. We performed a ret-
rospective assessment of the timing and risk factors of HBV reactivation among patients with resolved HBV
infection undergoing allogeneic HSCT between January 2000 and March 2008. HBV reactivation was defined
as development of positive hepatitis B surface antigen after transplant. Among the 61 patients with resolved
HBV infection before transplant (hepatitis B core antibody-positive, hepatitis B surface antigen-negative), 12
(19.7%) developed HBV reactivation. The cumulative probability of HBV reactivation 1, 2, and 4 years after
transplant was 9.0%, 21.7%, and 42.9%, respectively. In a time-dependent Cox model, the adjusted hazard
ratio (HR) of HBV reactivation for patients with pretransplant hepatitis B surface antibody levels \10
milli-international units per milliliter (mIU/mL) was 4.56 (95% confidence interval [CI] 1.23-16.9) compared
to those with levels $10 mIU/mL; the adjusted HR among patients who developed extensive chronic graft-
versus-host disease (cGVHD)was 7.21 (95%CI 1.25-41.5) compared to thosewho did not. HBV reactivation
is a common late complication among allogeneic HSCT recipients with pretransplant resolved infection.
Screening for HBV reactivation should be considered for at-risk HSCTrecipients. In this cohort, HBV reac-
tivation often developed in patients with cGVHD. Liver biopsy was useful in those patients with both to de-
lineate the contribution of each to liver dysfunction.
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Reactivation of latent viral pathogens after alloge-
neic hematopoetic stem cell transplantation (HSCT) is
a significant clinical problem. Viral pathogens such as
cytomegalovirus (CMV) predictably reactivate and
cause disease at high rates following allogeneic
HSCT. Hepatitis B virus (HBV) infection is of partic-
ular interest after allogeneicHSCTbecause it is a com-
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6/j.bbmt.2009.05.001been infected with HBV, and it causes chronic infec-
tion in over 350 million people [1]. In the last 2 de-
cades, several cancer centers in regions endemic for
HBV have reported reactivation of HBV characterized
by a significant rise in HBV virus load and develop-
ment of hepatitis after HSCT in patients who were
asymptomatic chronic carriers of HBV prior to trans-
plantation [2-4].
HBV reactivation has also been reported after
allogeneic HSCT in recipients with evidence of
resolved HBV prior to transplantation, where resolved
HBV infection is indicated by negative hepatitis B sur-
face antigen (HBsAg), positive hepatitis B core anti-
body (HBcAb), and/or positive hepatitis B surface
antibody (HBsAb) in the absence of prior HBV vacci-
nation [3-17]. Historically, clearance of HBsAg after
HBV infection, in conjunction with the appearance
of HBsAb, signaled resolution of HBV infection.
However, multiple studies have demonstrated that
HBV can persist in the liver and in peripheral blood
mononuclear cells (PBMCs) for years after serologic
resolution of the infection [18-21]. These reservoirs
are likely the source for HBV reactivation in this pop-
ulation, which is characterized by redevelopment of
circulating HBsAg and HBV with or without1049
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vation phenomenon has also been termed ‘‘reverse se-
roconversion’’ in HSCT recipients who were HBsAb
positive prior to transplantation and subsequently
lose HBsAb positivity in conjunction with redevelop-
ment of circulating HBsAg after transplantation [7].
Several case series and small studies have attempted
to assess the incidence, risk factors, and timing of HBV
reactivation in the allogeneic HSCT population. The
reported cumulative incidence of HBV reactivation
among allogeneic HSCT recipients with evidence of
resolved HBV varies between studies, ranging from
6% to 86% [7,10-12,14-16]. Several small studies
have suggested a variety of possible precipitating fac-
tors including HBsAb negative serologic status of the
donor [7,10], development of chronic graft-versus-host
disease (cGVHD) [5,11-13], corticosteroid exposure
after HSCT [10], and loss of protective native HBsAb
after HSCT [10,14-17]. In addition, small case series
have suggested that the risk of reactivation persists
for years after transplantation [10,14,16]. However,
these findings are limited by the short duration of fol-
low-up in many studies and the small number of
patients included in most studies. Furthermore, there
are no data or guidelines available to direct subsequent
assessment andmanagement of activeHBV infection in
this specific population [22-25].
In the present study, we assessed the potential pre-
cipitating factors and timing of HBV reactivation in
a large cohort of patients with a history of resolved
HBV infection who subsequently underwent alloge-
neic HSCT at our institution. We also described the
clinical characteristics and treatment history of the
subjects who developed HBV reactivation during
follow-up.MATERIALS AND METHODS
Patients
All adult patients who underwent allogeneic
HSCT at the Dana-Farber Cancer Institute/Brigham
and Women’s Hospital (DFCI/BWH) between Janu-
ary 1, 2000, and March 31, 2008, were included in
this analysis. Patients were identified as having re-
solved HBV infection if they were HBcAb positive,
HBsAg negative, and HBV virus load negative on pre-
transplant evaluation. Patients who were HBsAb posi-
tive and HBcAb negative were not considered to have
resolved HBV infection because DFCI/BWH is not in
an HBV-endemic area, and, therefore, most patients
who are HBsAb positive in the absence of other hepa-
titis B markers have been vaccinated for HBV and have
not been previously exposed to HBV.
The DFCI/BWH stem cell transplant database
and electronicmedical records were reviewed for cova-
riates and outcomes of interest including: age at thetime of transplantation, sex, birthplace, reason for
HSCT pretransplant infection status of chronic hepa-
titis C virus (HCV) and human immunodeficiency
virus (HIV), transplant conditioning regimen, donor
relatedness, human leukocyte antigen (HLA) donor
matching, stem cell source, development and maximal
grade of acute GVHD (aGVHD), development and
grade of cGVHD, pretransplant HBsAb measure-
ments, and use of posttransplant immunosuppressive
therapy including corticosteroids and rituximab. Pa-
tient data were censored at death or on December 1,
2008. The Office for Human Research Studies at the
DFCI/BWH approved this study.
Transplant conditioning regimens were classified
as either myeloablative (MA) or reduced intensity
(RIC) based on the conditioning agents used. During
the study period, MA regimens at DFCI/BWH typi-
cally included cyclophosphamide (Cy) and total body
irradiation (TBI). The standard RIC regimen at the
DFCI/BWH during the study period typically in-
cluded low-dose busulfan (Bu) and fludarabine (Flu).
Donors were considered HLA matched if 6 of 6
HLA-A, -B, and -DRB1 were identical. aGVHD was
graded according to the consensus grading system
[26]. cGVHD was graded by the system proposed by
Shulman et al. [27]. HBsAb was treated as a dichoto-
mous variable; the groupings included patients who
were HBV immune with HBsAb $10 milli-interna-
tional units per milliliter (mIU/mL) and patients
who were not immune with HBsAb \10 mIU/mL
[28].
Among those cohort members who developed
HBV reactivation after HSCT, information was col-
lected regarding assessment and treatment of HBV
including: liver biopsy results, alanine aminotransfer-
ase (ALT) results, HBV virus load and genotype,
HBV antigen tests including hepatitis Be antigen
(HBeAg) and HBsAg, HBV serologic tests, including
hepatitis Be antibody and HBsAb, and duration and
choice of antiviral therapy directed at HBV infection.HBV Testing
All stem cell donors are routinely tested for HBsAg
and HBcAb prior to donation, according to standard
blood donation screening procedures in the United
States [29]. HBsAb is not part of these standard screen-
ing procedures, and was not routinely measured in
stem cell donors during the study period. All potential
HSCT recipients are routinely tested for HBcAb and
HBsAg prior to transplantation. Those potential
recipients who are HBcAb positive on initial screen
are also subsequently tested for HBsAb and HBV virus
load at our institution.
HBV reactivation was defined in our cohort as
development of positive HBsAg after transplantation
in recipients who had negative results before
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positive before transplantation were assessed for
HBV reactivation after transplant with HBsAg and
HBV virus load testing on the basis of signs, symp-
toms, or clinical suspicion at the discretion of his or
her primary transplant oncologist. In addition, begin-
ning in the Fall of 2004, recipients who were HBcAb
positive prior to transplantation were also intermit-
tently screened for HBV reactivation after transplant
with HBsAg andHBV virus load testing in the absence
of signs or symptoms.
Serum measurements of HBsAb were performed
using different assays during the study period. Most
measurements of HBsAb during the study period
were made by quantitative enzyme immunoassay
(Quest Diagnostics, Cambridge, MA) and a few were
made by the qualitative Vitros ECi immunometric
assay (Ortho Clinical Diagnostics, Rochester, NY).
Measurements of HBsAg and HBcAb were also
performed using different assays during the study
period. Measurements of HBcAb during the study
period were made using the Vitros ECi immunometric
assay (Ortho Clinical Diagnostics), chemiluminescent
immunoassay (Abbott Diagnostics, Abbott Park, IL).
or enzyme immunoassay (Abbott Diagnostics). Mea-
surements of HBsAg during the study period were
made using the Vitros ECi immunometric assay
(Ortho Clinical Diagnostics) or by chemiluminescent
immunoassay (Abbott Diagnostics).
HBV virus load was determined by real-time poly-
merase chain reaction (PCR) using Roche COBAS
TaqMan HBV Test (Roche, Basel, Switzerland)
between January 2000 and January 2008. After January
2008, HBV virus load was determined by the branched
DNA method (Mayo Medical Laboratories, Roches-
ter, MN). HBV genotyping of the S and POL genes
(Quest Diagnostics Nichols Institute, San Juan Capi-
strano, CA) was performed in patients with HBV reac-
tivation at the time reactivation was diagnosed and
when suspected resistance developed during therapy.Statistical Analysis
Baseline pretransplant and posttransplant charac-
teristics were initially compared by 2-sided Fisher’s
exact test or Wilcoxon rank-sum test where appropri-
ate. The incidence rate of HBV reactivation was deter-
mined, and its confidence interval was calculated by
Fisher’s method using OpenEpi version 2.2.1 (http://
www.openepi.com;Atlanta,GA).Kaplan-Meier curves
were calculated to determine the cumulative probabil-
ity of HBV reactivation. Possible predictors of HBV
reactivation identified in the initial analysis were evalu-
ated in univariate Cox proportional hazard models.
The hazard ratio (HR) and 95% confidence interval
(CI) were determined for each candidate covariate.
aGVHD and cGVHD were modeled as time-dependent covariates. Candidate covariates included
in multivariate analysis were limited to those closely
associated with HBV reactivation (P # .10) given the
number of events in the cohort. Statistical analyses
were performed using SAS version 9.1 (SAS Institute
Inc., Cary, NC).RESULTS
Baseline Characteristics
Of 1386 patients who underwent allogeneic
HSCT during the study period, 61 (4.4%) had evi-
dence of resolved HBV infection with positive HBcAb
prior to transplantation. Baseline pretransplant char-
acteristics of the cohort of patients with resolved
HBV infection prior to transplant are displayed in
Table 1. There were more men than women in this
cohort, and the majority of patients had underlying
acute or chronic leukemia as the reason for transplan-
tation. All patients with evidence of prior HBV infec-
tion were HIV negative and HBV virus load negative
at baseline. One patient had chronic HCV infection
prior to transplantation. Patients in this cohort were
followed for a median of 17.0 months (range: 2.0-
81.0 months).
HBV Reactivation
Twelve of the 61 patients in the at-risk cohort of
patients who were HBcAb positive prior to HSCT
developed HBV reactivation after transplantation
(cumulative incidence 19.7%). The patient with
chronic HCV infection prior to transplantation was
not among the 12 who developed HBV reactivation.
The incidence rate of HBV reactivation in this group
was 0.11 episodes per patient-year after transplanta-
tion (95% CI 0.55-1.85). The cumulative probability
of the HBV reactivation was 9.0% at 1 year, 21.7%
at 2 years, 30.4% at 3 years, and 42.9% at 4 years after
HSCT. HBV reactivation was diagnosed at a median
time of 17.5 months after HSCT (range: 4.4 to 46.9
months; interquartile range: 11.2 to 26.4 months).
Risk Factors for HBV Reactivation
There was no difference in the cumulative inci-
dence of HBV reactivation in the at-risk cohort based
on most baseline characteristics (Table 1). Patients
who developed HBV reactivation tended to be youn-
ger than those who did not (P5 .09). In addition,
recipients with HBsAb \10 mIU/mL before trans-
plantation were significantly more likely to develop
HBV reactivation during follow up than those who
had baseline HBsAb levels$ 10 mIU/mL (P5 .02).
The cumulative incidence of HBV reactivation in
the at-risk cohort based on posttransplant characteris-
ticswas also assessed (Table 2).Therewas nodifference
Table 1. Baseline Pretransplant Characteristics of HBcAb-Positive Allogeneic HSCT Cohor
Pretransplant Characteristics Reactivation N5 12 (%) No Reactivation N5 49 (%) Total N5 61 (%) P
Recipient age, years .09
Median 45 52 51
Range 32-62 19-71 19-71
Recipient sex 1.00
Male 9 (75) 34 (69) 43 (70)
Female 3 (25) 15 (31) 18 (30)
Reason for transplant .61
Acute leukemia or MDS 7 (58) 18 (37) 25 (41)
Chronic leukemia 3 (25) 15 (31) 18 (30)
Lymphoma or multiple myeloma 2 (17) 12 (24) 14 (23)
Nonmalignant* 0 (0) 4 (8) 4 (7)
Pre-transplant HBsAb† .02
HBsAb $10 mIU/mL 7 (64) 45 (94) 52 (88)
HBsAb <10 mIU/mL 4 (36) 3 (6) 7 (12)
Conditioning regimen .11
Reduced intensity‡ 4 (33) 30 (61) 34 (56)
Myeloablative§ 8 (67) 19 (39) 27 (44)
Donor relatedness .53
Related donor 7 (58) 23 (47) 30 (49)
Unrelated donor 5 (42) 26 (53) 31 (51)
HLA match¶ 1.00
Matched donor 10 (83) 41 (84) 51 (84)
Mismatched donor 2 (17) 8 (16) 10 (16)
Stem cell source .73
Peripheral blood 12 (100) 42 (86) 54 (89)
Bone marrow 0 (0) 5 (10) 5 (8)
Umbilical cord blood 0 (0) 2 (4) 2 (3)
MDS indicates myelodysplastic syndrome; HBsAb, hepatitis B surface antibody.
*Includes 3 patients with aplastic anemia and 1 with thalessemia major.
†Pretransplant HBsAb measurements were not available on two HSCTrecipients.
‡All patients undergoing reduced-intensity allogeneic HSCTwere conditioned with fludarabine (Flu) and low-dose busulfan (Bu) except: 1 patient con-
ditioned with Flu, low-dose Bu, and antithymocyte globulin (ATG); two patients conditioned with Flu, melphalan (Mel), and ATG; and 1 patient condi-
tioned with total body irradiation (TBI).
§All patients undergoing myeloablative allogeneic HSCTwere conditioned with cyclophosphamide (Cy) and TBI except: 3 patients conditioned with Cy
and ATG; 1 patient conditioned with cyclophosphamide (Cy), TBI, thiotepa, and ATG; and 1 patient conditioned with Cy and Bu.
¶Donors were considered HLA matched if 6/6 HLA-A, -B, and -DRB1 were identical.
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on the duration of corticosteroid exposure or receipt of
rituximab after transplantation.Nopatientswhodevel-
oped severe (grade II-IV) aGVHD went on to develop
HBV reactivation. Significantly more patients with ex-
tensive cGVHDafterHSCTdevelopedHBV reactiva-
tion in comparison to thosewith limited or no cGVHD
(P5 .003).
A Cox proportional hazard model analysis was per-
formed to assess risk factors for HBV reactivation in
a time-dependent manner. Because pretransplant
HBsAb measurements were not available for 2 patients
(one of whom developed HBV reactivation and 1 of
whom did not), these 2 patients were excluded from
this analysis. Severe aGVHD and extensive cGVHD
were modeled as time-varying covariates. A univariate
HR for each covariate associatedwithHBVreactivation
in the initial analysis (where P\ .2) is shown inTable 3.
The covariates closely associated with HBV reacti-
vation on univariate Coxmodeling, including develop-
ment of extensive cGVHD and pretransplant HBsAb
\10 mIU/mL, were assessed on multivariate analysis.
Both covariates were independently associated with
development of HBV reactivation. Patients in this
cohort who hadHBsAb levels below 10mIU/mL priorto transplant had an adjusted HR of 4.6 for developing
HBV reactivation after transplantation when com-
pared to those with pretransplant HBsAb levels $10
mIU/mL (95% CI 1.23-16.9; P5 .023). In addition,
those patients who developed extensive cGVHD after
transplantation had an adjusted HR of 7.2 for develop-
ing HBV reactivation than those who did not (95% CI
1.25-41.5; P5 .027).Clinical Characteristics of HBV Reactivation
The clinical characteristics of the 12 patients who
developed HBV reactivation are shown in Table 4.
Of the 12 patients who developed HBV reactivation
in the at-risk cohort, 11 developed chronic active
HBV infection, including 1 who had fulminant hepati-
tis at the diagnosis of HBV reactivation (Patient 1).
Only Patient 5 had transient HBV reactivation that
cleared in\6 months after detection without antiviral
treatment. In addition, only 1 patient developed a de-
tectable HBV virus load that preceded the detection of
HBsAg. Patient 5 developed a detectable HBV virus
load 139 days prior to development of positive HBsAg.
Ten of the 12 patients who developed HBV reacti-
vation had extensive cGVHD initially diagnosed 4 to
Table 2. Posttransplant Characteristics of HBcAb-Positive Allogeneic HSCT Cohort
Posttransplant Characteristics Reactivation N5 12 (%) No reactivation N5 49 (%) Total N5 61 (%) P
Acute GVHD .10
Grades 0-I 12 (100) 37 (76) 49 (80)
Grades II-IV 0 (0) 12 (24) 12 (20)
Chronic GVHD .003
None 2 (17) 25 (51) 27 (44)
Limited 0 (0) 10 (20) 10 (16)
Extensive 10 (83) 14 (29) 24 (39)
Posttransplant corticosteroids, days .54
Median duration 187 119 139
Interquartile range 62-385 21-359 22-359
Posttransplant rituximab* .40
Yes 3 (25) 7 (14) 10 (16)
No 9 (75) 42 (86) 51 (84)
GVHD indicates graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; HBcAb, hepatitis B core antibody.
*No patient who received rituximab had developed hepatitis B virus (HBV) reactivation before or at the time of infusion. Rituximab was administered for
the treatment of: extensive chronic GVHD, posttransplant lymphoproliferative disorder, immune-mediated hemolytic anemia, immune-mediated throm-
bocytopenia, or relapsed malignancy.
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who developed cGVHD were treated with corticoste-
roids initially. Adjunctive agents, including tacrolimus,
sirolimus, mycophenolate mofetil (MMF), rituximab,
or extracorporeal photopheresis, were added or the
dose was increased as dictated by the individual re-
sponse to steroids. The median time from diagnosis
of cGVHD, when increased immunosuppression
started, to HBV reactivation among these patients
was 12.5 months (range: 2-37 months). The immuno-
suppressive regimens during the 100 days prior to the
diagnosis of HBV reactivation are summarized in Ta-
ble 4. No patient had evidence of CMV viremia or dis-
ease within 100 days of the diagnosis of HBV
reactivation.
Although most patients in this group had HBsAb
levels well above 10 mIU/mL prior to HSCT, the
majority had HBsAb\10 mIU/mL by the time HBVTable 3. Proportional Hazards Modeling of Risk of HBV Reactivati
Characteristic Univariate HR (95% CI)
Age 0.992 (0.946-1.040)
Pretransplant HBsAb
HBsAb $10 mIU/mL
HBsAb < 10 mIU/mL 4.840 (1.357-17.260)
Conditioning regimen
Reduced intensity
Myeloablative 2.416 (0.704-8.284)
Acute GVHD†
Grade 0-I
Grade II-IV 0 (0-N)
Chronic GVHD
None or limited
Extensive 7.282 (1.341-39.549)‡
GVHD indicates graft-versus-host disease; HR, hazard ratio; CI, confidence inte
cell transplantation; HBsAb, hepatitis B surface antibody.
Pretransplant HBsAb measurements were unavailable for two patients in the at
not. This analysis includes only the 59 patients for whom pretransplant HBsA
*Only characteristics with P < .10 on univariate analysis were included in mult
†There were no patients in the cohort who developed grade II-IV aGVHD an
‡Univariate analysis of chronic GVHD in the entire cohort (including the two
statistically significant HR: 7.977 (1.498-42.476), P5.015.reactivation occurred. At the time of diagnosis, a ma-
jority of patients had abnormal ALT levels ranging
from just above the upper limit of normal to 10 times
the upper limit of normal. Two patients had no eleva-
tion of ALT at the time ofHBV reactivation, including
Patient 5, who cleared HBV viremia within a few
months during supportive care, and Patient 10, who
was the only patient who underwent T cell-depleted
transplantation in the cohort. With the exception of
Patient 9, who had HBV infection with a precore mu-
tant HBV and was HBeAg negative at the time of reac-
tivation, the other patients in the group were all
HBeAg positive at diagnosis. Ten of 12 patients under-
went baseline genotyping of the reactivating HBV.
Most patients in the cohort were genotype A or D.
Nine patients in the group underwent liver biopsy
shortly after diagnosis of HBV reactivation. Four
patients had evidence of liver fibrosis and 1 patienton after Allogeneic HSCT
P Multivariate HR (95% CI)* P
.73 — —
.015 4.558 (1.228-16.917) .023
.16 — —
1.00 — —
.022 7.210 (1.252-41.530) .027
rval; HBV, hepatitis B virus;—, not applicable; HSCT, hematopoietic stem
-risk cohort, including 1 who developed HBV reactivation and 1 who did
b was available.
ivariate analysis.
d HBV reactivation.
patients without available pretransplant HBsAb) results in a similar and
Table 4. Clinical Characteristics of HBcAb-Positive Allogeneic HSCT Recipients with HBV Reactivation
Patient
Number
Age,
Years Sex
Reason
for HSCT Birthplace
Chronic
GVHD Grade
Time to
Chronic GVHD
Diagnosis, Months*
Immuno suppression
Preceding 100 days
HBsAb at
Baseline,
mIU/mL
Time to
HBV Diagnosis,
Months
Laboratories at HBV Diagnosis
HBV Genotype
ALT,
U/L†
HBsAb,
mIU/mL HBeAg HBeAb
HBV VL,
LogIU/mL
1 37 F AML Brazil Extensive 11 Tac, ritux <10 27 532 <10 + - 8.54 ND
2 49 M ALL France Extensive 8 Pred, tac, sir <10 26 102 <10 + - >8.70 A
3 33 M CML Mexico Extensive 7 Pred, tac, sir $10 12 119 <10 + - 7.29 A
4 43 M NHL Dominican
Republic
Extensive 4 Pred taper <10 15 83 <10 + - 8.62 D
5 54 F NHL China None — Tac taper 18 5 29 12 + ND 3.81 ND
6 63 M AML USA Extensive 7 Pred taper $10 21 52 <10 + - 7.40 A
7 50 M MDS USA Extensive 9 Tac taper >150 20 160 10 + - 7.38 D
8 58 M CLL USA Extensive 7 Pred taper, tac >150 11 57 14 + - 7.43 D
9 42 M MDS China Extensive 10 Pred, tac taper,
mm, photopher
$10 47 109 <10 - + >8.70 C‡
10 53 M AML USA None — Ritux, TCD <10 4 16 <10 + - 7.14 A
11 40 M MDS USA Extensive 10 Pred taper, tac – 12 101 <10 + - >8.70 A
12 45 F CML USA Extensive 7 Pred, sir 19 39 65 <10 + - 8.69 D
GVHD indicates graft-versus-host disease; HBeAb, hepatitis B e antibody; VL, virus load; LogIU/mL, logarithm of international units per milliliter; F, female; AML, acute mylogenous leukemia; Tac, tacrolimus; ritux,
rituximab; +, positive; -, negative; ND, not determined; M, male; ALL, acute lymphoblastic leukemia; pred, prednisone; sir, sirolimus; CML, chronic mylogenous leukemia; NHL, non-Hodgkin lymphoma; —, not ap-
plicable; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; mm, mycophenolate mofetil; photopher, extracorporeal photopheresis; TCD, T cell-depleted transplant.
*Patients 5 and 10 did not develop chronic GVHD during follow-up.
†Normal range for alanine aminotransferase (ALT): 7-52.
‡Precore mutant.
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clinical diagnosis prior to biopsy differed from the di-
agnosis established by pathology. Patients 7 and 9 were
empirically treated for cGVHD of the liver over the
preceding months with increased immunosuppression
until the diagnosis of HBV was established by sero-
logic testing and liver biopsy. Four patients (Patients
1, 4, 6, and 11) had simultaneous evidence of GVHD
and HBV infection in varying patterns on histology.
HBV Treatment
The majority of the patients with reactivation
(11/12) were treated with antiviral medications di-
rected atHBVduring follow up (Table 5). Ten patients
were treated with entecavir monotherapy. The first
patient diagnosedwithHBV reactivation in the cohort,
Patient 1, was treatedwith adefovir and lamivudine, the
2 medications that were FDA approved for HBV treat-
ment at the time of diagnosis in 2004.
One HSCT recipient with HBV reactivation,
patient 5, did not develop chronic HBV infection and
was not treated with any antiviral medications directed
at HBV. Patient 5 had a normal ALT and, unlike the
other cohort members with HBV reactivation, also
had a relatively low HBV virus load (\10,000 interna-
tional units permilliliter [IU/mL] or 4 logarithms of in-
ternational units per milliliter [logIU/mL]) at the time
of reactivation. This patient was monitored clinically
and subsequently reconverted to HBsAg negative and
HBV virus load negative within 4 months.
Response to HBV Treatment
Most patients in the cohort who were treated for
HBV had a biochemical response to treatment with
normalization of ALT shortly after initiation of treat-
ment. Among the 11 patients who were treated with
antiviral therapy, 9 started therapy at least 6 months
before the end of follow-up. Three of 9 (33%) achieved
undetectable HBV virus loads by 6 months after the
start of therapy. Four of the 6 patients who had detect-
able HBV viremia at 6 months of therapy had low virus
loads, under 2,000 IU/mL (3.30 logIU/mL) consistent
with a partial virologic response [24].
Six patients with HBV reactivation in the cohort
were started on antiviral therapy at least 12 months
before the end of follow-up. Three of these 6 (50%)
achieved undetectable HBV virus loads by 12 months
after the start of antiviral therapy. Interestingly, 2 of
the 3 patients with detectable HBV virus loads 12
months after the start of therapy (Patients 3 and 8)
developed a complete response to therapy with clear-
ance of HBV virus load, loss of HBeAg, and loss of
HBsAg with continued therapy after 21 and 16
months. Conversely, Patient 6 who had an undetect-
able HBV virus load 12 months after starting therapy
redeveloped a low detectable HBV virus load (\3.30logIU/mL) despite unchanged antiviral therapy 14
months after therapy was initiated.
By the end of follow-up, 7 of 11 patients (64%)
treated for HBV reactivation in this cohort achieved
a virologic response to therapy with undetectable
HBV virus loads and negative HBeAg in those treated
for more than 6 months, and declining virus loads in
those treated for\6 months. Most notably, 4 of the
patients with virologic response (36% of those treated
for HBV reactivation) also had a ‘‘complete’’ response
to therapy with loss of HBsAg during follow-up [22].
Patient 1 lost HBsAg after 49 months of therapy
with adefovir and lamivudine. Patients 3, 7, and 8
lost HBsAg after 21, 8, and 16 months of therapy
with entecavir, respectively. Three of these 4 devel-
oped robust titers of HBsAb, ranging from 98 to 244
mIU/mL in association with clearance of HBsAg and
circulating HBV. All 3 who redeveloped HBsAb cur-
rently remain HBsAg negative off of antiviral therapy.
No patient treated with antiviral medications
directed at HBV developed serious side effects related
to HBV treatment including lactic acidosis or hepatic
flare during follow-up. Four patients had an incomplete
response to entecavir therapy. Patients 2 and 6 had low
(\3.3 logIU/mL), butdetectableHBVvirus loads at the
end of follow-up, 8 and 23 months after starting ther-
apy, respectively. Both were continued on entecavir
monotherapy. Patient 4 had a persistent HBV virus
load between 3.3 and 4.0 logIU/mL after 2 years of en-
tecavir monotherapy despite an initial decline in HBV
virus load. There was no indication of poor compliance
with therapy and genotypic analysis revealed no drug-
associated resistance mutations. The patient was con-
tinuedon entecavirmonotherapy. After 7months of en-
tecavirmonotherapy, Patient 10 developed a significant
increase inHBV virus load (.1 logIU/mL) after an ini-
tial response.Clinically, therewas no indication of non-
compliance with entecavir. HBV genotype revealed no
medication-associated resistance mutations. The pa-
tient was continued on entecavir, and tenofovir was
added to the antiviral regimen.
Survival
The 1-year survival in the HBcAb-positive cohort
was 70.3%. Overall, 35 (57%) patients survived to the
end of follow-up, 20 (33%) died, and 6 (10%) were
censored (because of transfer of care from this center
to a local facility). There were no HBV-associated
deaths in the cohort.DISCUSSION
These data demonstrate that reactivation of HBV
is a frequent, but usually late complication of trans-
plantation among patients with serologic evidence of
resolved HBV infection prior to allogeneic HSCT.
Table 5. Histologic and Treatment-Associated Characteristics of HBcAb-Positive Allogeneic HSCT Recipients with HBV Reactivation
Patient
Number
Diagnosis
Preliver
Biopsy*
Diagnosis
Postliver
Biopsy†
Fibrosis
Stage
Treatment
Regimen
HBV VL
6 Months
after Treatment
Started, LogIU/mL
HBV VL
12 Months
after Treatment
Started,
LogIU/mL
Laboratory Values at Last Follow-up
Decrease in
HBV VL at Last
Follow- up,
LogIU/mL
Duration
Treatment,
Months
Hepatitis Status
at Last Follow-up
ALT,
U/L‡
HBsAb,
mIU/mL HBeAb HBeAg
HBV VL,
LogIU/mL
1 HBV HBV +
GVHD
0§ Lamivudine +
adefovir
< Assay < Assay 14 244 — — < Assay 8.54 49 Complete response
2 HBV HBV 0 Entecavir 3.14 — 25 <10 ND + 3.14 5.56 8, on going¶ Incomplete response
3 — — — Entecavir 2.94 2.22 51 98 ND - < Assay 7.29 21 Complete response
4 GVHD GVHD +
HBV
2 Entecavir 4.33 3.56 29 <10 — + 3.72^ 4.90 28, on going Incomplete response
5 — — — Supportive care — — 15 <10 ND ND < Assay 3.81 — Resolution
6 GVHD HBV +
GVHD
2 Entecavir 3.12 < Assay 41 <10 — + 3.04 4.36 23, on going Incomplete response
7 GVHD HBV 3 Entecavir < Assay < Assay 33 101 + — < Assay 7.38 8 Complete response
8 GVHD GVHD 0 Entecavir 2.09 3.80 44 <10 + — <Assay 7.43 16, on going Complete response
9 GVHD HBV 3 Entecavir < Assay — 41 <10 + — < Assay 8.70 11, on going Virologic response
10 — — — Entecavir 6.04 — 48 <10 — + 5.59^ 1.55 8, on going Incomplete response
11 GVHD GVHD +
HBV
0 Entecavir — — 100 <10 — + 4.19 4.51 5, on going Virologic response#
12 HBV HBV 0 Entecavir — — 76 <10 — + 6.23 2.46 3, on going Virologic response
GVHD indicates graft-versus-host disease; HBeAb, hepatitis B e antibody; VL, virus load; LogIU/mL, logarithm of international units per milliliter; F, female; AML, acute mylogenous leukemia; Tac, tacrolimus; ritux,
rituximab; +, positive; -, negative; ND, not determined; M, male; ALL, acute lymphoblastic leukemia; pred, prednisone; sir, sirolimus; CML, chronic mylogenous leukemia; NHL, non-Hodgkin lymphoma; —, not ap-
plicable; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; mm, mycophenolate mofetil; photopher, extracorporeal photopheresis; TCD, T cell-depleted transplant.
*Patients 3, 5, and 10 did not undergo liver biopsy.
†Where there are two diagnoses listed, the first is the predominant pattern appreciated on liver biopsy.
‡Normal range for alanine aminotransferase (ALT): 7-52.
§Wide-spread hepatic necrosis.
¶Patient transferred care to another institution in conjunction with a move 8 months into HBV therapy.
^HBV genotype performed for increased virus load after initial response; no medication-associated resistance mutations found.
#Virologic response determined by reduction in HBV virus load by over 1 logIU/mL after 3 months of therapy in these patients with <6 months of follow-up after initiation of antiviral therapy [24].
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Biol Blood Marrow Transplant 15:1049-1059, 2009 1057HBV Reactivation following Allogeneic HSCTThe cumulative risk of HBV reactivation rose by 9%
to 13% per year of survival after transplantation in
this cohort, to give a cumulative probability of 43%
at 4 years after HSCT. Overall survival did not seem
to be affected by pretransplant-resolved HBV infec-
tion when compared to other cohorts at our center
[30].
We identify 2 significant independent risk factors
for the development of HBV reactivation after
HSCT: low pretransplant HBsAb levels and develop-
ment of cGVHDafter transplantation. HBsAb is a sur-
rogate for HBV immunity; HBsAb of 10 mIU/mL is
typically considered the threshold for protection
from HBV infection [28]. Although most patients in
the cohort had protective levels of HBsAb prior to
HSCT, the risk for HBV reactivation among the few
cohort members with pretransplant HBsAb below
10 mIU/mL prior to transplant was nearly 5 times
greater than the risk for those with HBsAb at or above
the threshold of 10 mIU/mL before HSCT.
The immunologic reason why recipient-derived
humoral immunity would have a long-term protective
effect against HBV reactivation after allogeneic
HSCT is not completely clear. It is possible that devel-
opment of high levels of HBsAb after the initial HBV
infection in some patients reflects true clearance of the
HBV virus, and thus some of HSCT recipients with
high levels of HBsAb prior to transplant may not be
truly at risk for HBV reactivation. Alternatively, high
levels of HBsAb at the time of HSCT may prevent
HBV reactivation in the initial posttransplant period,
when the recipient is most immunocompromised,
allowing the recipient to remain free of HBV
reactivation until new donor-derived immunity to
HBV can develop.
Development of cGVHDwas also a strong predic-
tor of HBV reactivation in this cohort, which confirms
the findings of Seth et al. [11], who first reported
a significant association between cGVHD and HBV
reactivation. This study further delineates that the
grade of cGVHD is predictive, as suggested in the
case series by Knoll et al. [12]. In our cohort patients
who developed extensive cGVHD were 7 times more
likely to develop HBV reactivation than those with
limited or no cGVHD.
Of the 12 patients who developed HBV reactiva-
tion during follow up, 10 had extensive cGVHD at
the time of HBV diagnosis, many of whom were tem-
porally clinically diagnosed with liver involvement of
cGVHD before they were diagnosed with HBV reac-
tivation. To clarify the contribution of cGVHD versus
HBV to the liver disease present in these patients, 9 of
12 patients with HBV reactivation underwent liver
biopsy shortly after HBV reactivation was diagnosed.
Notably, the prebiopsy clinical diagnosis did not fully
agree with the definitive diagnosis established by
biopsy in 6 of 9 cases. Furthermore, 4 had evidenceof both active HBV and active GVHD on biopsy.
These findings suggest that there may be a complex
relationship between active HBV infection and
cGVHD of the liver after transplantation. Although
the immune dysregulation associated with cGVHD
and subsequent immunosuppressive therapy aimed at
treating GVHD may lead to HBV reactivation, it is
also possible that chronic active HBV replication stim-
ulates an immunologic response that leads to localized
GVHD. Further studies are needed to delineate this
relationship. In addition, these findings highlight the
important role that liver biopsy may play in the assess-
ment and subsequent management of allogeneic
HSCT patients with HBV reactivation. Similar to
the present study, Ma et al. [31] also found that liver
biopsy was useful for targeting therapy among patients
with cGVHD in a cohort of HSCT patients with
a high prevalence of HBV infection.
Although not all patients in this cohort met criteria
for treatment of HBV based on the current treatment
guidelines proposed for nonimmunocompromised
hosts [22-24], given the potential synergistic effects
of HBV andGVHD on the liver and the immunocom-
promised status of the patients in our cohort, treat-
ment was pursued in most patients. Ten of 12
patients who developedHBV reactivation were treated
with entecavir monotherapy, which resulted in viro-
logic response in 6 of 10 patients (60%). Most notably,
3 of the patients treated with entecavir monotherapy
(30%) developed a complete response to therapy,
with loss of HBsAg and durable clearance of HBV
virus load. An additional patient treated with adefovir
and lamivudine also achieved a complete response.
The overall rate of complete response in the patients
who were treated in this cohort, including patients
treated for\1 year, was 36% (4/11), which is high in
comparison to the 5% rate reported with entecavir
after 2 years of therapy and adefovir after 4 to 5 years
of therapy [25]. This high overall rate of complete
response to HBV therapy may be a reflection of the
unique immunologic situation in allogeneic HSCT
recipients in which the immune function of the recip-
ient (who developed the initial HBV infection) is
replaced by that of the donor. Donor immunity prior
to HSCT may have an impact on the ability of
HSCT recipients with HBV reactivation to regain im-
munologic control of the infection, but needs to be
studied further.
Donor immunity may also have an impact on the
overall risk of HBV reactivation. Because pretrans-
plant HBsAb was not routinely checked in stem cell
donors during the study period (and is not part of rou-
tine blood donor screening in the United States [29])
one of the limitations of this study is that we were un-
able to assess the impact of pretransplant donor
HBsAb serologic status on the subsequent risk of
HBV reactivation. Several studies have suggested
1058 Biol Blood Marrow Transplant 15:1049-1059, 2009S. P. Hammond et al.that donor immunity to HBV, acquired by donor vac-
cination or natural infection, may protect against HBV
reactivation after HSCT [7,10]. This has led to the
suggestion that vaccination of the donor prior to trans-
plant may be a strategy to prevent later HBV reactiva-
tion in the recipient [7]. However, at least one group
has reported HBV reactivation with an escape mutant
in an HSCT recipient transplanted with stem cells
from a vaccinated donor [16]. Further studies are
needed to determine the role that donor immunity
plays in recipient development of HBV reactivation
and to determine if HBV vaccination of the donor
prior to HSCT would be helpful to prevent this com-
plication.
We were also limited in this study because serial
screening measurements of HBsAb, HBsAg, and
HBV virus load were only performed in a subset of
patients during posttransplant follow-up. Others
have shown that HBV viremia may precede frank reac-
tivation with development of positive HBsAg [12], but
in the absence of serial HBV virus load measurements
after HSCT in the entire cohort, we were unable to
systematically assess for this. Furthermore, as demon-
strated in a few patients in this cohort, HBV reactiva-
tion can occur in the absence of ALT abnormalities
and can resolve without intervention. Thus, it is possi-
ble we underestimated the frequency of HBV reactiva-
tion in this cohort, as some, but not all, patients were
routinely screened for HBV in the absence of ALT el-
evation or clinical symptoms.
In addition, without serial HBsAb measurements
after transplantation, no assessment of the trend in
HBsAb levels and its impact on the risk of HBV reac-
tivation could be performed. Several groups have re-
ported that levels of HBsAb decline after HSCT and
have suggested this that may lead to increased suscep-
tibility to HBV reactivation [14,17]. In response to this
finding, one group assessed HBV vaccination in 12 pa-
tients previously exposed to HBV after HSCT and re-
ported that posttransplant vaccination may prevent
HBV reactivation [32]. However, from the criteria
used for vaccination, patients with extensive cGVHD,
who are most susceptible to HBV reactivation, would
have been excluded from vaccination in that study
and postvaccination follow-up was short. Further
studies that include patients with extensive cGVHD
are needed to clarify the impact of loss of HBsAb after
transplantation and recipient HBV vaccination after
transplantation on the risk of HBV reactivation.
Last, this analysis was also limited by the size of the
cohort. Although this is the largest study to date
assessing HBV reactivation in HSCT recipients with
resolved HBV infection prior to transplantation, like
other studies, there was a relatively small number of
outcomes in the cohort. In addition, in this small
cohort, there was only 1 patient who underwent a T
cell-depleted transplant, so we were unable to assessthe impact of this type of GVHD prophylaxis on the
risk of HBV reactivation.
In summary, HBV reactivation is a common late
complication of allogeneic HSCT. Low levels of
HBsAb prior to transplantation and development of
extensive cGVHD are strong independent predictors
of increased risk for HBV reactivation. Based on these
findings, periodic post-HSCT screening for HBV
reactivation with HBsAg, HBsAb, and HBV virus
load should be considered in patients with evidence
of resolved HBV prior to transplant, particularly those
who have low HBsAb levels prior to transplantation
and those who develop extensive cGVHD after trans-
plantation. In patients who do develop HBV reactiva-
tion after transplant and have suspected or proven
cGVHD, liver biopsy can be useful to delineate the
degree of liver disease caused by each process. Further
studies in this population are needed to determine
when therapy should be initiated, particularly in the
setting of liver GVHD, and which regimen is optimal.
In this cohort, entecavir monotherapy was effective in
most patients to achieve a biochemical and virologic
response and 30% of patients treated with entecavir
achieved complete response to therapy with loss of
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